Immunodiagnostics Market by Product (Reagents, Instruments, and Software & Services), Technology (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Chemiluminescence Immunoassay, Fluorescent Immunoassay, Rapid Test, and Others) - Global Opportunity Analysis and Industry Forecasts, 2014-2022
Immunodiagnostics or immunoassay is a key technique of in vitro diagnostics that deals with the diagnosis of various diseases based on antigen-antibody reaction. Immunodiagnostics is an analytical technique, which employs antibodies as reagents against the antigens to be detected. The result of immunodiagnostics test aids in diagnosing. It also has clinical application in the field of infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others. The test is usually performed in laboratories and hospitals from patient’s biological specimen such as blood, urine, stool, or other body fluid to detect diseased condition and infection.
The key drivers for the market growth include rise in incidence of chronic and infectious diseases along with the growth in geriatric population, technological advancements such as fully automated and more capable immunoassay platforms and increase in need for accurate, target specific, and rapid diagnostic tests. In addition, rise in demand for next generation immunodiagnostics platform and popularity of personalized medicine is poised to augment the growth of immunodiagnostics market globally. However, high cost of sophisticated immunodiagnostics test, stringent government regulations, and reluctance in adoption of advanced technologies in emerging economies are few factors that impede the market growth. The world immunodiagnostics market is projected reach $17,836 Million by 2022, from $10,738 Million growing at a CAGR of 7.3% from 2016 to 2022
The world immunodiagnostics market is segmented on the basis of product, technology, application, end user, and geography. Based on product, the market is divided into reagents, instruments, and services & software. Reagents segment has the largest market share, owing to high cost of the immunoassay reagents (such as enzyme and substrate) and technological advancements in reagents for accurate and specific results. Based on technology, the market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), fluorescent immunoassay (FIA), radioimmunoassay (RIA), rapid test, and others. ELISA holds the highest share in the technology market owing to the technological advancements such as automated platforms for ELISA, continues development in biomarkers and cost benefits. Nevertheless, CLIA exhibit the highest growth owing to the technological innovation such as automated platforms offering highly accurate results. Based on application, the immunodiagnostics market is classified into infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others. Among these, infectious disease segment is the highest revenue contributor, while oncology & endocrinology segment grow at a fastest rate, during the forecast period. On the basis of end user, the immunodiagnostics market is segmented into hospitals, laboratories, academics & research universities, pharma & biotech industries among others.
The geographical segmentation of the market includes North America, Europe, Asia-Pacific, and LAMEA. In 2015, North America accounted for the largest market share in the immunodiagnostics market and is estimated to retain its dominant position throughout the forecast period. The growth in this region is mainly due to the factors such as product innovations, sophisticated healthcare infrastructure, U.S.-being the target area for the top players in the market owing to high prevalence rate of chronic diseases and increase in geriatric population. Nevertheless, Asia-Pacific region is expected to emerge as the area with maximum growth potential due to the rise in number of infectious diseases, increase in chronic diseases, presence of high unmet needs, and increased focus of key players towards emerging markets such as China and India, and increased healthcare expenditure for the development of improved healthcare infrastructure.
Product development and launch is the mostly adopted strategy in the immunodiagnostics market followed by acquisition. The report provides a comprehensive analysis of the key players that operate in the world immunodiagnostics market.
KEY MARKET BENEFITS
By Product
The key drivers for the market growth include rise in incidence of chronic and infectious diseases along with the growth in geriatric population, technological advancements such as fully automated and more capable immunoassay platforms and increase in need for accurate, target specific, and rapid diagnostic tests. In addition, rise in demand for next generation immunodiagnostics platform and popularity of personalized medicine is poised to augment the growth of immunodiagnostics market globally. However, high cost of sophisticated immunodiagnostics test, stringent government regulations, and reluctance in adoption of advanced technologies in emerging economies are few factors that impede the market growth. The world immunodiagnostics market is projected reach $17,836 Million by 2022, from $10,738 Million growing at a CAGR of 7.3% from 2016 to 2022
The world immunodiagnostics market is segmented on the basis of product, technology, application, end user, and geography. Based on product, the market is divided into reagents, instruments, and services & software. Reagents segment has the largest market share, owing to high cost of the immunoassay reagents (such as enzyme and substrate) and technological advancements in reagents for accurate and specific results. Based on technology, the market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), fluorescent immunoassay (FIA), radioimmunoassay (RIA), rapid test, and others. ELISA holds the highest share in the technology market owing to the technological advancements such as automated platforms for ELISA, continues development in biomarkers and cost benefits. Nevertheless, CLIA exhibit the highest growth owing to the technological innovation such as automated platforms offering highly accurate results. Based on application, the immunodiagnostics market is classified into infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others. Among these, infectious disease segment is the highest revenue contributor, while oncology & endocrinology segment grow at a fastest rate, during the forecast period. On the basis of end user, the immunodiagnostics market is segmented into hospitals, laboratories, academics & research universities, pharma & biotech industries among others.
The geographical segmentation of the market includes North America, Europe, Asia-Pacific, and LAMEA. In 2015, North America accounted for the largest market share in the immunodiagnostics market and is estimated to retain its dominant position throughout the forecast period. The growth in this region is mainly due to the factors such as product innovations, sophisticated healthcare infrastructure, U.S.-being the target area for the top players in the market owing to high prevalence rate of chronic diseases and increase in geriatric population. Nevertheless, Asia-Pacific region is expected to emerge as the area with maximum growth potential due to the rise in number of infectious diseases, increase in chronic diseases, presence of high unmet needs, and increased focus of key players towards emerging markets such as China and India, and increased healthcare expenditure for the development of improved healthcare infrastructure.
Product development and launch is the mostly adopted strategy in the immunodiagnostics market followed by acquisition. The report provides a comprehensive analysis of the key players that operate in the world immunodiagnostics market.
KEY MARKET BENEFITS
- The study provides an in-depth analysis of the world immunodiagnostics market with current trends and future estimations to elucidate the imminent investment pockets.
- The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the market, by product, helps understand various types of devices used for the treatment of infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others.
- Competitive intelligence highlights the business practices followed by the leading market players across various geographies.
- Porters Five Force’s model will interpret the bargaining power of suppliers and buyers, threat of new entrants and substitutes, and competition amongst the key players.
By Product
- Reagents
- Instruments
- Software & Services
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Fluorescent Immunoassay (FIA)
- Radioimmunoassay (RIA)
- Rapid Test
- Others
- Infectious Diseases
- Oncology & endocrinology
- Hepatitis & retrovirus
- Bone & mineral
- Autoimmunity,
- Cardiac biomarker
- Others
- Clinical Laboratories
- Hospitals
- Academic & Research Centers
- Pharmaceutical & Biotechnology Industry
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
- Abbott Laboratories
- Immunodiagnostic Systems Holdings Plc (IDS)
- DiaSorin S.p.A.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Siemens AG
- Sysmex Corporation
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Arkray, Inc.
- Arkray, Inc.,
- Alere, Inc.,
- Merck Millipore,
- Becton, Dickinson and Company,
- Biomerieux SA,
- Medicaroid Corporation,
- Qiagen NV,
- Affimetrix,
- ImmunoDX,
- Meridian Bioscience
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 Value chain analysis
3.5 Government regulations
3.6 Market share analysis, 2015
3.7 Market Dynamics
3.7.1 Drivers
3.7.1.1 Rising incidence of chronic and infectious diseases and a growing geriatric population
3.7.1.2 Technological advancements
3.7.1.3 Increasing need for accurate, precise and rapid diagnostic tests
3.7.1.4 Growing demand for next generation immunodiagnostics platform
3.7.1.5 Demand for personalized medicine
3.7.2 Restraints
3.7.2.1 High cost of immunodiagnostic products
3.7.2.2 Stringent government regulations
3.7.2.3 Reluctance in adoption of advanced technologies in emerging economies
3.7.3 Opportunities
3.7.3.1 Presence of large unmet diagnostic needs in emerging economies
3.7.3.2 Conjunction of personalized and point of care technologies
CHAPTER 4 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Reagents
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Instrument
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Services & software
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Enzyme-linked immunosorbent assay (ELISA)
5.2.1 Market size and forecast
5.3 Chemiluminescence immunoassay (CLIA)
5.3.1 Market size and forecasts
5.4 Radioimmunoassay (RIA)
5.4.1 Market size and forecast
5.5 Fluorescence immunoassay (FIA)
5.5.1 Market size and forecast
5.6 Rapid tests
5.6.1 Market size and forecast
5.7 Others
5.7.1 Market size and forecast
CHAPTER 6 WORLD IMMUNODIAGNOSTICS MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Infectious diseases
6.2.1 Market size and forecast
6.3 Oncology and endocrinology
6.3.1 Market size and forecast
6.4 Bone and mineral diseases
6.4.1 Market size and forecast
6.5 Autoimmunity disorders
6.5.1 Market size and forecast
6.6 Cardiac biomarkers
6.6.1 Market size and forecast
6.7 Drug monitoring
6.7.1 Market size and forecast
6.8 Other applications
6.8.1 Market size and forecast
CHAPTER 7 WORLD IMMUNODIAGNOSTICS MARKET, BY END USERS
7.1 Overview
7.1.1 Market size and forecast
7.2 Clinical laboratories
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 Hospitals
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 Academic and research centers
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 Pharmaceutical and biotechnology industry
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
7.6 Others
7.6.1 Key market trends
7.6.2 Key growth factors and opportunities
7.6.3 Market size and forecast
CHAPTER 8 IMMUNODIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
8.2.4.1 U.S.Market size and forecast
8.2.4.2 canada Market size and forecast
8.2.5.3 Mexico Market size and forecast
8.3 Europe
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast
8.3.3.1 Germany Market size and forecast
8.3.3.2 France Market size and forecast
8.3.3.3 U.K.Market size and forecast
8.3.3.4 Rest of Europe Market size and forecast
8.4 Asia-Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.4.3.1 India Market size and forecast
8.4.3.2 China Market size and forecast
8.4.3.3 Japan Market size and forecast
8.4.3.4 Australia Market size and forecast
8.5 LAMEA
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
8.5.3.1 Latin America Market size and forecast
8.5.3.2 Middle East Market size and forecast
8.5.3.3 Africa Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Operating Business Segments
9.1.4 Business Performance
9.1.5 Key Strategic Moves & Developments
9.2 Siemens AG
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Operating Business Segments
9.2.4 Financial Performance
9.2.5 Key Strategic Moves and Developments
9.3 Immunodiagnostic Systems Holdings Plc
9.3.1 Company Overview
9.3.2 Company Snapshot
9.3.3 Operating Business Segments
9.3.4 Business Performance
9.3.5 Key Strategic Moves & Developments
9.4 DiaSorin S.p.A.
9.4.1 Company Overview
9.4.2 Operating Business Segments
9.4.3 Business Performance
9.4.4 Key Strategic Moves & Developments
9.5 Johnson & Johnson Services, Inc.
9.5.1 Company Overview
9.5.2 Operating Business Segments
9.5.3 Business Performance
9.5.4 Key Strategic Moves & Developments
9.6 F. Hoffmann-La Roche Ltd
9.6.1 Company Overview
9.6.2 Operating Business Segments
9.6.3 Business Performance
9.6.4 Key Strategic Moves & Developments
9.7 Sysmex Corporation
9.7.1 Company Overview
9.7.2 Operating Business Segments
9.7.3 Business Performance
9.7.4 Key Strategic Moves & Developments
9.8 Danaher Corporation(Beckman Coulter)
9.8.1 Company Overview
9.8.2 Company Snapshot
9.8.3 Operating Business Segments
9.8.4 Business Performance
9.8.5 Key Strategic Moves and Developments
9.9 Thermo Fisher Scientific Inc.
9.9.1 Company Overview
9.9.2 Company Snapshot
9.9.3 Operating Business Segments
9.9.4 Business Performance
9.9.5 Key Strategic Moves and Developments
9.10 Bio-Rad Laboratories, Inc.
9.10.1 Company Overview
9.10.2 Company Snapshot
9.10.3 Operating Business Segments
9.10.4 Business Performance
9.10.5 Key Strategic Moves and Developments
Other players in the value chain include (profiles not included in the report)
Arkray, Inc., Alere, Inc., Merck Millipore, Becton, Dickinson and Company, Biomerieux SA, Medicaroid Corporation, Qiagen NV, Affimetrix, ImmunoDX, Meridian Bioscience
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 Value chain analysis
3.5 Government regulations
3.6 Market share analysis, 2015
3.7 Market Dynamics
3.7.1 Drivers
3.7.1.1 Rising incidence of chronic and infectious diseases and a growing geriatric population
3.7.1.2 Technological advancements
3.7.1.3 Increasing need for accurate, precise and rapid diagnostic tests
3.7.1.4 Growing demand for next generation immunodiagnostics platform
3.7.1.5 Demand for personalized medicine
3.7.2 Restraints
3.7.2.1 High cost of immunodiagnostic products
3.7.2.2 Stringent government regulations
3.7.2.3 Reluctance in adoption of advanced technologies in emerging economies
3.7.3 Opportunities
3.7.3.1 Presence of large unmet diagnostic needs in emerging economies
3.7.3.2 Conjunction of personalized and point of care technologies
CHAPTER 4 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Reagents
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Instrument
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Services & software
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Enzyme-linked immunosorbent assay (ELISA)
5.2.1 Market size and forecast
5.3 Chemiluminescence immunoassay (CLIA)
5.3.1 Market size and forecasts
5.4 Radioimmunoassay (RIA)
5.4.1 Market size and forecast
5.5 Fluorescence immunoassay (FIA)
5.5.1 Market size and forecast
5.6 Rapid tests
5.6.1 Market size and forecast
5.7 Others
5.7.1 Market size and forecast
CHAPTER 6 WORLD IMMUNODIAGNOSTICS MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Infectious diseases
6.2.1 Market size and forecast
6.3 Oncology and endocrinology
6.3.1 Market size and forecast
6.4 Bone and mineral diseases
6.4.1 Market size and forecast
6.5 Autoimmunity disorders
6.5.1 Market size and forecast
6.6 Cardiac biomarkers
6.6.1 Market size and forecast
6.7 Drug monitoring
6.7.1 Market size and forecast
6.8 Other applications
6.8.1 Market size and forecast
CHAPTER 7 WORLD IMMUNODIAGNOSTICS MARKET, BY END USERS
7.1 Overview
7.1.1 Market size and forecast
7.2 Clinical laboratories
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 Hospitals
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 Academic and research centers
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 Pharmaceutical and biotechnology industry
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
7.6 Others
7.6.1 Key market trends
7.6.2 Key growth factors and opportunities
7.6.3 Market size and forecast
CHAPTER 8 IMMUNODIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
8.2.4.1 U.S.Market size and forecast
8.2.4.2 canada Market size and forecast
8.2.5.3 Mexico Market size and forecast
8.3 Europe
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast
8.3.3.1 Germany Market size and forecast
8.3.3.2 France Market size and forecast
8.3.3.3 U.K.Market size and forecast
8.3.3.4 Rest of Europe Market size and forecast
8.4 Asia-Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.4.3.1 India Market size and forecast
8.4.3.2 China Market size and forecast
8.4.3.3 Japan Market size and forecast
8.4.3.4 Australia Market size and forecast
8.5 LAMEA
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
8.5.3.1 Latin America Market size and forecast
8.5.3.2 Middle East Market size and forecast
8.5.3.3 Africa Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Operating Business Segments
9.1.4 Business Performance
9.1.5 Key Strategic Moves & Developments
9.2 Siemens AG
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Operating Business Segments
9.2.4 Financial Performance
9.2.5 Key Strategic Moves and Developments
9.3 Immunodiagnostic Systems Holdings Plc
9.3.1 Company Overview
9.3.2 Company Snapshot
9.3.3 Operating Business Segments
9.3.4 Business Performance
9.3.5 Key Strategic Moves & Developments
9.4 DiaSorin S.p.A.
9.4.1 Company Overview
9.4.2 Operating Business Segments
9.4.3 Business Performance
9.4.4 Key Strategic Moves & Developments
9.5 Johnson & Johnson Services, Inc.
9.5.1 Company Overview
9.5.2 Operating Business Segments
9.5.3 Business Performance
9.5.4 Key Strategic Moves & Developments
9.6 F. Hoffmann-La Roche Ltd
9.6.1 Company Overview
9.6.2 Operating Business Segments
9.6.3 Business Performance
9.6.4 Key Strategic Moves & Developments
9.7 Sysmex Corporation
9.7.1 Company Overview
9.7.2 Operating Business Segments
9.7.3 Business Performance
9.7.4 Key Strategic Moves & Developments
9.8 Danaher Corporation(Beckman Coulter)
9.8.1 Company Overview
9.8.2 Company Snapshot
9.8.3 Operating Business Segments
9.8.4 Business Performance
9.8.5 Key Strategic Moves and Developments
9.9 Thermo Fisher Scientific Inc.
9.9.1 Company Overview
9.9.2 Company Snapshot
9.9.3 Operating Business Segments
9.9.4 Business Performance
9.9.5 Key Strategic Moves and Developments
9.10 Bio-Rad Laboratories, Inc.
9.10.1 Company Overview
9.10.2 Company Snapshot
9.10.3 Operating Business Segments
9.10.4 Business Performance
9.10.5 Key Strategic Moves and Developments
Other players in the value chain include (profiles not included in the report)
Arkray, Inc., Alere, Inc., Merck Millipore, Becton, Dickinson and Company, Biomerieux SA, Medicaroid Corporation, Qiagen NV, Affimetrix, ImmunoDX, Meridian Bioscience
LIST OF TABLES
TABLE 1 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 2 WORLD IMMUNODIAGNOSTICS REAGENTS AND CONSUMABLES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3 WORLD IMMUNODIAGNOSTICS INSTRUMENTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4 WORLD IMMUNODIAGNOTICS SOFTWARE & SERVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5 WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 6 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 7 WORLD ELISA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 WORLD CLIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 WORLD RIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10 WORLD FIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 WORLD RAPID TEST MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 WORLD OTHER TECHNOLOGIES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 WORLD IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 14 WORLD IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 WORLD IMMUNODIAGNOSTICS MARKET FOR ONCOLOGY AND ENDOCRINOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 WORLD IMMUNODIAGNOSTICS MARKET FOR BONE AND MINERAL DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 WORLD IMMUNODIAGNOSTICS MARKET FOR AUTOIMMUNITY DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 WORLD IMMUNODIAGNOSTICS MARKET FOR CARDIAC BIOMARKERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 WORLD IMMUNODIAGNOSTICS MARKET FOR DRUG MONITORING, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 WORLD IMMUNODIAGNOSTICS MARKET FOR OTHER APPLICTIONS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21 WORLD UMMUNODIAGNOSTICS MARKET, BY END USER, 20142022, ($MILLION)
TABLE 22 WORLD IMMUNODIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 WORLD IMMUNODIAGNOSTICS MARKET FOR HOSPITALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24 WORLD IMMUNODIAGNOSTICS MARKET FOR ACADEMIC AND RESEARCH CENTERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25 WORLD IMMUNODIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26 WORLD IMMUNODIAGNOSTICS MARKET FOR OTHER END USER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 27 WORLD IMMUNODIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 28 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 30 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 31 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 32 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 33 U.S.: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 34 CANADA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 35 MEXICO: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 36 EUROPE IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37 EUROPE IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 38 EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 39 EUROPE IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 40 EUROPE IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 41 GERMANY: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 42 FRANCE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 43 U.K.: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 44 REST OF EUROPE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 45 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 46 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 47 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 48 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 49 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 50 INDIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 51 CHINA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 52 JAPAN: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 53 AUSTRALIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 54 LAMEA IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 55 LAMEA IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 56 LAMEA IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 57 LAMEA IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 58 LAMEA IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 59 LATIN AMERICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 60 MIDDLE EAST: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 61 AFRICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 62 ABBOTT: COMPANY SNAPSHOT
TABLE 63 ABBOTT: OPERATING SEGMENTS
TABLE 64 SIEMENS-COMPANY SNAPSHOT
TABLE 65 SIEMENS-OPERATING SEGMENTS
TABLE 66 IDS-COMPANY SNAPSHOT
TABLE 67 IDS: OPERATING SEGMENTS
TABLE 68 DIASORIN-COMPANY SNAPSHOT
TABLE 69 DIASORIN OPERATING SEGEMENTS
TABLE 70 JOHNSON & JOHNSON COMPANY SNAPSHOT
TABLE 71 JOHNSON & JOHNSON OPERATING SEGEMENTS
TABLE 72 ROCHE - COMPANY SNAPSHOT
TABLE 73 ROCHE - OPERATING SEGMENTS
TABLE 74 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 75 SYSMEX CORPORATION - OPERATING SEGMENTS
TABLE 76 DANAHER - COMPANY SNAPSHOT
TABLE 77 DANAHER - OPERATING SEGMENTS
TABLE 78 THERMO FISHER -COMPANY SNAPSHOT
TABLE 79 THERMO FISHER - OPERATING SEGMENTS
TABLE 80 BIO-RAD-COMPANY SNAPSHOT
TABLE 81 BIO-RAD: OPERATING SEGMENTS
TABLE 1 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 2 WORLD IMMUNODIAGNOSTICS REAGENTS AND CONSUMABLES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3 WORLD IMMUNODIAGNOSTICS INSTRUMENTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4 WORLD IMMUNODIAGNOTICS SOFTWARE & SERVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5 WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 6 WORLD IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 7 WORLD ELISA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 WORLD CLIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 WORLD RIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10 WORLD FIA MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 WORLD RAPID TEST MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 WORLD OTHER TECHNOLOGIES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 WORLD IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 14 WORLD IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 WORLD IMMUNODIAGNOSTICS MARKET FOR ONCOLOGY AND ENDOCRINOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 WORLD IMMUNODIAGNOSTICS MARKET FOR BONE AND MINERAL DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 WORLD IMMUNODIAGNOSTICS MARKET FOR AUTOIMMUNITY DISEASES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 WORLD IMMUNODIAGNOSTICS MARKET FOR CARDIAC BIOMARKERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 WORLD IMMUNODIAGNOSTICS MARKET FOR DRUG MONITORING, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 WORLD IMMUNODIAGNOSTICS MARKET FOR OTHER APPLICTIONS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21 WORLD UMMUNODIAGNOSTICS MARKET, BY END USER, 20142022, ($MILLION)
TABLE 22 WORLD IMMUNODIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 WORLD IMMUNODIAGNOSTICS MARKET FOR HOSPITALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24 WORLD IMMUNODIAGNOSTICS MARKET FOR ACADEMIC AND RESEARCH CENTERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25 WORLD IMMUNODIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26 WORLD IMMUNODIAGNOSTICS MARKET FOR OTHER END USER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 27 WORLD IMMUNODIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 28 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 30 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 31 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 32 NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 33 U.S.: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 34 CANADA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 35 MEXICO: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 36 EUROPE IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37 EUROPE IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 38 EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 39 EUROPE IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 40 EUROPE IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 41 GERMANY: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 42 FRANCE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 43 U.K.: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 44 REST OF EUROPE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 45 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 46 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 47 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 48 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 49 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 50 INDIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 51 CHINA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 52 JAPAN: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 53 AUSTRALIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 54 LAMEA IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 55 LAMEA IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
TABLE 56 LAMEA IMMUNODIAGNOSTICS MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 57 LAMEA IMMUNODIAGNOSTICS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 58 LAMEA IMMUNODIAGNOSTICS MARKET, BY END USER, 2014-2022 ($MILLION)
TABLE 59 LATIN AMERICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 60 MIDDLE EAST: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 61 AFRICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
TABLE 62 ABBOTT: COMPANY SNAPSHOT
TABLE 63 ABBOTT: OPERATING SEGMENTS
TABLE 64 SIEMENS-COMPANY SNAPSHOT
TABLE 65 SIEMENS-OPERATING SEGMENTS
TABLE 66 IDS-COMPANY SNAPSHOT
TABLE 67 IDS: OPERATING SEGMENTS
TABLE 68 DIASORIN-COMPANY SNAPSHOT
TABLE 69 DIASORIN OPERATING SEGEMENTS
TABLE 70 JOHNSON & JOHNSON COMPANY SNAPSHOT
TABLE 71 JOHNSON & JOHNSON OPERATING SEGEMENTS
TABLE 72 ROCHE - COMPANY SNAPSHOT
TABLE 73 ROCHE - OPERATING SEGMENTS
TABLE 74 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 75 SYSMEX CORPORATION - OPERATING SEGMENTS
TABLE 76 DANAHER - COMPANY SNAPSHOT
TABLE 77 DANAHER - OPERATING SEGMENTS
TABLE 78 THERMO FISHER -COMPANY SNAPSHOT
TABLE 79 THERMO FISHER - OPERATING SEGMENTS
TABLE 80 BIO-RAD-COMPANY SNAPSHOT
TABLE 81 BIO-RAD: OPERATING SEGMENTS
LIST OF FIGURES
FIG. 1 TOP INVESTMENT POCKETS IN IMMUNODIAGOSTICS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (20142016)
FIG. 3 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 4 TOP WINNING STRATEGIES: NATURE AND COMPANY
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN ANALYSIS FOR IMMUNODIAGNOSTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS: IMMUNODIAGNOSTICS MARKET, 2015
FIG. 8 RESTRAINTS AND DRIVERS: WORLD IMMUNODIAGNOSTICS MARKET
FIG. 9 GLOBAL INCIDENCE OF DISEASES
FIG. 10 IMMUNODIAGNOSTICS TECHNOLOGY
FIG. 11 GENERAL CLASSIFICATION OF INFECTIOUS DISEASES
FIG. 12 ESTIMATED NUMBER OF CANCER DEATHS BY SEX, U.S., 2016
FIG. 13 ESTIMATED NUMBER OF HIV RELATED DEATHS, SOUTH AFRICA, 2016
FIG. 14 ABBOTT: NET SALES, 20132015 ($MILLION)
FIG. 15 ABBOTT: REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 16 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 17 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 18 SEIMENS: REVENUE, 2013-2015, ($MILLION)
FIG. 19 SEIMENS: REVENUE BY SEGMENT, 2015 (%)
FIG. 20 SEIMENS: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 21 IDS: REVENUE, 2013-2016, ($MILLION)
FIG. 22 IDS: REVENUE, BY BUSINESS SEGMENTS, 2016 (%)
FIG. 23 IDS: REVENUE, BY GEOGRAPHY, 2016, (%)
FIG. 24 DIASORIN: REVENUE, 2013-2015, ($MILLION)
FIG. 25 DIASORIN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 26 DIASORIN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 27 DIASORIN: STRATEGY SHARE, 2014-2016 (%)
FIG. 28 JOHNSON & JOHNSON: REVENUE, 2013-2015, ($MILLION)
FIG. 29 JOHNSON & JOHSNON: REVENUES BY SEGMENTS (2015)
FIG. 30 JOHNSON & JOHSNON: REVENUES BY GEOGRAPHY (2015)
FIG. 31 JOHNSON & JOHSNON: STRATEGY SHARE, 2014-2016 (%)
FIG. 32 ROCHE: NET SALES, 20132015 ($MILLION)
FIG. 33 ROCHE: REVENUEBY BUSINESS SEGMENTS, 2015 (%)
FIG. 34 ROCHE: REVENUEBY GEOGRAPHY, 2015 (%)
FIG. 35 SYSMEX CORPORATION: REVENUE, 2013-2015, ($MILLION)
FIG. 36 SYSMEX CORPORATION, % REVENUE, BY BUSINESS SEGMENT (2015)
FIG. 37 SYSMEX CORPORATION, % REVENUE BY GEOGRAPHY (2015)
FIG. 38 SYSMEX CORPORATION: STRATEGY SHARE, 2014-2016 (%)
FIG. 39 DANAHER: NET SALES, 20132015 ($MILLION)
FIG. 40 DANAHER: REVENUEBY BUSINESS SEGMENTS, 2015 (%)
FIG. 41 DANAHER: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 42 THERMO FISHER: REVENUE BUSINESS SEGMENTS, 2015 (%)
FIG. 43 THERMO FISHER: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 44 THERMO FISHER: REVENUE, 2013- 2015, ($MILLION)
FIG. 45 BIO-RAD: REVENUE, 20132015, ($MILLION)
FIG. 46 BIO-RAD: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 47 BIO-RAD: REVENUE, BY GEOGRAPHY, 2015, (%)
FIG. 48 BIO-RAD: STRATEGY SHARE, 2014-2016 (%)
FIG. 1 TOP INVESTMENT POCKETS IN IMMUNODIAGOSTICS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (20142016)
FIG. 3 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 4 TOP WINNING STRATEGIES: NATURE AND COMPANY
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN ANALYSIS FOR IMMUNODIAGNOSTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS: IMMUNODIAGNOSTICS MARKET, 2015
FIG. 8 RESTRAINTS AND DRIVERS: WORLD IMMUNODIAGNOSTICS MARKET
FIG. 9 GLOBAL INCIDENCE OF DISEASES
FIG. 10 IMMUNODIAGNOSTICS TECHNOLOGY
FIG. 11 GENERAL CLASSIFICATION OF INFECTIOUS DISEASES
FIG. 12 ESTIMATED NUMBER OF CANCER DEATHS BY SEX, U.S., 2016
FIG. 13 ESTIMATED NUMBER OF HIV RELATED DEATHS, SOUTH AFRICA, 2016
FIG. 14 ABBOTT: NET SALES, 20132015 ($MILLION)
FIG. 15 ABBOTT: REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 16 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 17 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 18 SEIMENS: REVENUE, 2013-2015, ($MILLION)
FIG. 19 SEIMENS: REVENUE BY SEGMENT, 2015 (%)
FIG. 20 SEIMENS: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 21 IDS: REVENUE, 2013-2016, ($MILLION)
FIG. 22 IDS: REVENUE, BY BUSINESS SEGMENTS, 2016 (%)
FIG. 23 IDS: REVENUE, BY GEOGRAPHY, 2016, (%)
FIG. 24 DIASORIN: REVENUE, 2013-2015, ($MILLION)
FIG. 25 DIASORIN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 26 DIASORIN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 27 DIASORIN: STRATEGY SHARE, 2014-2016 (%)
FIG. 28 JOHNSON & JOHNSON: REVENUE, 2013-2015, ($MILLION)
FIG. 29 JOHNSON & JOHSNON: REVENUES BY SEGMENTS (2015)
FIG. 30 JOHNSON & JOHSNON: REVENUES BY GEOGRAPHY (2015)
FIG. 31 JOHNSON & JOHSNON: STRATEGY SHARE, 2014-2016 (%)
FIG. 32 ROCHE: NET SALES, 20132015 ($MILLION)
FIG. 33 ROCHE: REVENUEBY BUSINESS SEGMENTS, 2015 (%)
FIG. 34 ROCHE: REVENUEBY GEOGRAPHY, 2015 (%)
FIG. 35 SYSMEX CORPORATION: REVENUE, 2013-2015, ($MILLION)
FIG. 36 SYSMEX CORPORATION, % REVENUE, BY BUSINESS SEGMENT (2015)
FIG. 37 SYSMEX CORPORATION, % REVENUE BY GEOGRAPHY (2015)
FIG. 38 SYSMEX CORPORATION: STRATEGY SHARE, 2014-2016 (%)
FIG. 39 DANAHER: NET SALES, 20132015 ($MILLION)
FIG. 40 DANAHER: REVENUEBY BUSINESS SEGMENTS, 2015 (%)
FIG. 41 DANAHER: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 42 THERMO FISHER: REVENUE BUSINESS SEGMENTS, 2015 (%)
FIG. 43 THERMO FISHER: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 44 THERMO FISHER: REVENUE, 2013- 2015, ($MILLION)
FIG. 45 BIO-RAD: REVENUE, 20132015, ($MILLION)
FIG. 46 BIO-RAD: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 47 BIO-RAD: REVENUE, BY GEOGRAPHY, 2015, (%)
FIG. 48 BIO-RAD: STRATEGY SHARE, 2014-2016 (%)
